Celldex Therapeutics, Inc.
A clinical-stage biotechnology company that makes antibody-based medicines designed to calm overactive immune responses behind inflammatory, allergic, and autoimmune conditions. Its lead drug candidate, barzolvolimab, targets a receptor on mast cells to treat chronic hives and other mast-cell-driven diseases. The company was born in 2008 when AVANT Immunotherapeutics merged with a private firm, and its name blends "cell" with the pharma-style "-dex" suffix.
Sold 2.35M
Bought 30.3K
Granted 18.5K
Granted 10.0K
Granted 307.0K · Bought 10.0K · Sold 233.3K
Granted 12.0K · Bought 5.0K
Granted 56.2K · Bought 35.0K · Sold 17.7K
Granted 152.9K · Sold 132.3K
Granted 56.2K · Bought 3.0K · Sold 17.7K
Granted 60.2K · Bought 3.0K · Sold 17.7K
Granted 129.4K · Bought 69.3K · Sold 120.0K
Granted 100.5K · Sold 91.9K
Granted 38.5K
Granted 116.1K · Bought 9.8K · Sold 93.9K
Granted 41.7K · Bought 430 · Sold 12.9K
Granted 28.5K
Granted 22.7K · Bought 34.5K · Sold 16.9K
Granted 19.3K
Granted 83.6K · Bought 2.1K · Sold 68.6K
Granted 109.6K · Bought 1.0K · Sold 98.3K
Granted 66.8K · Bought 1.1K · Sold 68.2K
Granted 10.0K
Granted 5.9K
Granted 2.0K · Bought 25.0K
Granted 10.0K · Bought 48.3K
Granted 4.0K · Bought 40.0K · Sold 56.2K
Granted 5.9K · Bought 2.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Medarex Inc10% owner · 2 transactions | — | 2.96Mas of Jun 2009 | — | — | 2.35M |
| Ryan Una SPresident & CEO, Director · 4 transactions | — | 899.2Kas of Jul 2007 | — | 30.3K | — |
| van den Broek RichardDirector · 3 transactions | — | 233.5Kas of Jun 2016 | 18.5K | — | — |
| McMahon Gerald PhDDirector · 23 transactions | — | 180.7Kas of Dec 2018 | 10.0K | — | — |
| Catlin Avery WSr. VP & CFO · 21 transactions | — | 83.6Kas of Sep 2016 | 307.0K | 10.0K | 233.3K |
| Shannon Timothy MDirector · 10 transactions | — | 83.2Kas of Jun 2014 | 12.0K | 5.0K | — |
| Ellberger LarryDirector · 22 transactions | — | 73.5Kas of Jun 2017 | 56.2K | 35.0K | 17.7K |
| Wright Richard M.Former Officer · 15 transactions | — | 70.1K | 152.9K | — | 132.3K |
| Penner Harry JrDirector · 12 transactions | — | 41.9Kas of Jun 2017 | 56.2K | 3.0K | 17.7K |
| Lipton Karen ShoosDirector · 13 transactions | — | 41.8Kas of Jun 2017 | 60.2K | 3.0K | 17.7K |
| Marucci Anthony SPRESIDENT & CEO, Director · 36 transactions | — | 40.3Kas of Nov 2024 | 129.4K | 69.3K | 120.0K |
| Crowley ElizabethSR. VP & CPDO · 14 transactions | — | 39.1Kas of Jun 2024 | 100.5K | — | 91.9K |
| Conrad Herbert JDirector · 9 transactions | — | 38.5Kas of Jun 2017 | 38.5K | — | — |
| Martin Samuel BatesSVP AND CFO · 26 transactions | — | 32.9K | 116.1K | 9.8K | 93.9K |
| Jimenez Freddy A.SVP & GENERAL COUNSEL · 9 transactions | — | 30.8K | 41.7K | 430 | 12.9K |
| Elston GeorgeDirector · 8 transactions | — | 28.5Kas of Jun 2016 | 28.5K | — | — |
| Keler TiborEXECUTIVE VP & CSO · 8 transactions | — | 24.2Kas of Dec 2022 | 22.7K | 34.5K | 16.9K |
| Pepin RonaldSR. VP & CBO · 2 transactions | — | 20.1K | 19.3K | — | — |
| Young Diane C.SVP, CHIEF MEDICAL OFFICER · 8 transactions | — | 17.1Kas of Jun 2024 | 83.6K | 2.1K | 68.6K |
| Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS · 13 transactions | — | 13.4Kas of Jun 2024 | 109.6K | 1.0K | 98.3K |
| Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN. · 16 transactions | — | 12.6Kas of May 2024 | 66.8K | 1.1K | 68.2K |
| Brownlie Keith LDirector · 1 transaction | — | 10.0Kas of Jun 2017 | 10.0K | — | — |
| Newbold Ronald CSr. VP, Business Dev. · 1 transaction | — | 5.9Kas of Jan 2009 | 5.9K | — | — |
| Schaller Charles RDirector · 7 transactions | — | 5.0Kas of Sep 2010 | 2.0K | 25.0K | — |
| Freeman Paula RSr.Dir.Human Resources · 2 transactions | — | 3.0Kas of Jan 2008 | — | — | — |
| Marino James JDirector · 4 transactions | — | 2.2Kas of Nov 2024 | 10.0K | 48.3K | — |
| Parekh Rajesh RDirector · 6 transactions | — | 2.0Kas of Sep 2010 | 4.0K | 40.0K | 56.2K |
| Keilani TahaVP Medical & Reg Affairs · 2 transactions | — | 2.0Kas of Jan 2008 | — | — | — |
| Davis Thomas AndrewSr. VP & CMO · 3 transactions | — | 1.5Kas of Sep 2010 | 5.9K | 2.5K | — |
| Lorantis Holdings LTD10% owner · 1 transaction | — | 0as of Apr 2008 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -3.08M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.